Responses were similar among patients with estrogen patches and ARPIs compared to luteinizing hormone releasing hormone ...

Aversa Fentanyl holds the potential to become the world’s first abuse-deterrent opioid patch.

ORLANDO - Nutriband Inc. (NASDAQ:NTRB), a developer of transdermal pharmaceutical products, has announced an exclusive partnership with Kindeva Drug Delivery to develop Aversa™ Fentanyl, a potential ...

Nutriband and Kindeva formalize exclusive product development partnership and long-term commitment based on shared development costs in exchange for milestone payments Nutriband is partnering with ...

Prostate cancer cells usually require male androgen hormones, such as testosterone, to grow. Androgen deprivation therapy ...

When prostate cancer patients need therapy to reduce male hormone levels, delivering some of the treatment via a patch on the skin may be just as effective as traditional means of administration with ...

A mid-stage study reveals that transdermal estradiol patches may match traditional androgen deprivation therapy in treating prostate cancer with fewer side effects. This approach boosts bone density ...

Nutriband Inc. (the “Company”)(NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced World and European Wrestling Gold medalist and Olympic Silver medalist ...

Since the new year, the FDA has announced 24 recalls nationwide, as well as some regional recalls that affect in Oklahoma. Here's what we know.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

The FDA announced a very serious recall. A product sold in New York can cause serious, life threatening, or fatal respiratory ...

ORLANDO - Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical products with a market capitalization of $74 million, announced Monday that it has received a Notice of ...